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Abstract 
Background & aims: Coeliac disease (CD) is an autoimmune disorder 
triggered by the ingestion of gluten, affecting 1% of the population and 
presenting with gastrointestinal symptoms, weight loss and anemia. We 
evaluated the presence of neurological deficits and investigated if the 
presence of TG6 autoantibodies increases the risk of neurological 
involvement in patients with newly diagnosed CD presenting to 
gastroenterologists.  
Methods: Prospective cohort study at a secondary care gastroenterology 
centre. Neurological evaluation included neurological history, examination, 
MRI brain, MR spectroscopy of the cerebellum and serological measurements 
for TG6 autoantibodies. The first half of patients recruited underwent repeat 
MR spectroscopy at one year after gluten-free diet (GFD). 
Results: 100 patients with newly diagnosed CD were recruited. Gait instability 
was reported in 24%, persisting sensory symptoms in 12%, and frequent 
headaches in 42% of patients. Gait ataxia was found in 29%, nystagmus in 
11% and distal sensory loss in 10%. 60% had abnormal MRI with abnormal 
MR spectroscopy of the cerebellum in 47%, and/or brain white matter lesions 
above what is expected from age in 25%. 40% of patients had circulating TG6 
autoantibodies and displayed significant atrophy of subcortical brain regions, 
when compared to patients without TG6 autoantibodies. In those patients with 
abnormal spectroscopy, repeat MR spectroscopy of the cerebellum at 1 year 
revealed improvement following GFD.  
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Conclusions: In newly diagnosed patients with CD presenting to 
gastroenterologists, neurological deficits are common as are autoantibodies to 
TG6. The significantly reduced regional brain volume in patients with TG6 
autoantibodies provides evidence for a direct link between autoimmunity to 
TG6 and brain atrophy in CD.  
Keywords: coeliac disease; neurological dysfunction; TG6 antibodies; brain 
imaging 
 
What You Need to Know 
Background: Patients with CD can sometimes present exclusively with 
neurological dysfunction but little is known of any neurological involvement at 
the time of diagnosis of classic CD in patients presenting to 
gastroenterologists. 
Findings: In adult patients with CD presenting to gastroenterologists, 
neurological deficits are very common at the time of diagnosis. The presence 
of TG6 autoantibodies (a neuronal expressed transglutaminase) in these 
patients is associated with regional brain atrophy. 
Implications for patient care: These findings further emphasize the need for 
early diagnosis of CD and strict adherence to a gluten-free diet in order to 
avoid permanent neurological disability.   
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Introduction 
 
Coeliac Disease (CD) is an autoimmune disorder triggered by the ingestion of 
gluten in genetically susceptible individuals. It affects 1% of the population.1 
CD belongs to the spectrum of gluten-related disorders that encompass 
diverse manifestations including Dermatitis Herpetiformis (DH), and 
neurological dysfunction, the commonest of which is gluten ataxia (GA).2  
It remains unclear as to why in some patients the initial presentation is with 
gastrointestinal symptoms of bloating, abdominal pain, diarrhea, and weight 
loss, whilst in others it is primarily or exclusively with an itchy vesicular skin 
rash (as in DH) or with neurological manifestations such as GA.3,4,5  
One possible explanation may lie in the primary immunological response 
targeting different potential auto-antigens (transglutaminases) and thus driving 
the respective type of primary clinical manifestation. This would be in keeping 
with the discovery of TG2 being the autoantigen in CD, TG3 the autoantigen 
in DH and TG6 the autoantigen in neurological manifestations.6,7,8,9  
The degree of overlap between CD and extraintestinal clinical manifestations 
remains unknown, as does the potential for future development of such 
manifestations with continuous exposure to gluten.  
It is generally assumed that neurological symptoms and dysfunction in 
patients with newly diagnosed classical CD presenting to gastroenterologists 
are rare. To our knowledge, no study has utilized both detailed neurological 
examination and brain imaging with MR spectroscopy to systematically 
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evaluate large numbers of patients with classical CD presenting to the 
gastroenterologists for any neurological dysfunction.  
The primary aim of this study was therefore to establish if TG6 autoimmunity 
in the context of newly diagnosed CD patients is a marker of current 
neurological dysfunction. Secondly to establish the true prevalence of 
neurological involvement as identified by detailed brain imaging and 
neurological clinical history and examination at the time of diagnosis of CD, in 
patients presenting to gastroenterology clinics. Thirdly to prospectively study 
any changes on neuroimaging 12 months after the diagnosis of CD and the 
introduction of gluten-free diet (GFD).  
 
Methods  
Patient selection and clinical assessments 
This was a 3-year prospective study based at the Department of 
Gastroenterology, Academic Department of Neurosciences and Academic 
Department of Neuroradiology, Sheffield Teaching Hospitals NHS Trust, 
Sheffield, UK. The study (STH18452) was approved by the South Yorkshire 
Research Ethics Committee and informed consent was obtained from all 
participants. All patients were referred by their General Practitioners for 
investigation of possible CD to a dedicated gastroenterology clinic run by one 
of the authors (DSS). All patients were from the catchment area of the 
Sheffield Teaching Hospitals NHS Trust.  
Consecutive patients with newly diagnosed CD following gastroscopy and 
duodenal biopsy were approached for participation during their 
gastroenterology appointment immediately after the biopsy results confirming 
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CD became available. A history of previous neurological diagnosis was an 
exclusion criterion for enrollment into the study, although none of the patients 
that agreed to participate had a prior history of any secondary care 
neurological consultation or diagnosis.  
 
Neurological history and clinical examination 
All patients were clinically assessed by Consultant Neurologists, including 
detailed neurological history and examination. The Neurologists were blinded 
to the neuro-radiological findings and to the serological results for TG6 
autoantibodies (these were performed after the initial clinical assessment). As 
part of their neurological history patients were specifically asked if they had 
experienced any balance problems (gait instability, tendency to fall, 
clumsiness), persisting sensory symptoms (tingling, numbness, peripheral 
pain in feet and hands) or frequent (weekly) headaches. If there was any 
clinical evidence of a peripheral neuropathy on clinical examination (distal 
sensory disturbance and/or areflexia) patients underwent detailed 
neurophysiological assessments done by 2 of the authors, PZ and PGS, 
Consultant Neurophysiologists, to verify the presence or not of any 
neuropathy. The clinical neurological examination included detailed 
assessment of gait, including ability to tandem walk and stand on each leg in 
turn.  
 
Brain imaging  
Patients underwent MR imaging of the brain, including volumetric T1 weighted 
and volumetric FLAIR structural imaging, and MR spectroscopy of the 
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cerebellum (vermis and hemisphere). The methodology of MR imaging, MR 
spectroscopy and the cut-offs for abnormal spectroscopic measurements of 
N-Acetyl Aspartate to Creatine ratio (NAA/Cr) have been described  
previously.10 The white matter disease on MRI was analysed by 2 of the 
authors, NH and DC, neuroradiologists with over 10 years’ experience at 
specialist neuroradiology consultant level. Both neuroradiologists were 
blinded to the TG6 serological status of the patients at the time of reporting. 
Scans were graded using the Fazekas scoring system and the individual 
number of white matter hyperintensities recorded from the volumetric FLAIR 
images, with discrepancies resolved by consensus.11 Imaging data from 525 
healthy volunteers (collected by the neuroradiology department) was used to 
correct for age related changes in morphometric assessments as detailed 
below. The first 52 patients recruited underwent repeat scanning using the 
same protocol at 1 year after the initial diagnosis and the introduction of a 
gluten-free diet.  
Volumetry of key grey matter (GM) brain regions was based on processing of 
T1 images to generate normalized brain volume (NBV; volume as a 
percentage of total intracranial volume) data sets. Briefly, to obtain cerebral 
grey matter (GM) volumes the “recon_all” pipeline from Freesurfer 
(http://surfer.nmr.mgh.harvard.edu/) was used.12 Cerebellar GM volumes were 
derived using the cerebellum-dedicated “SUIT” pipeline 
(http://www.diedrichsenlab.org/imaging/suit.htm).13 All volume measures were 
converted to NBV using the eTIV variable from Freesurfer output. Significant 
findings were further interrogated by age-controlled volumetry of sub-regions, 
and “vertex” shape analysis via “FIRST” (a part of FSL) where appropriate. 
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Detailed methodology for image processing used is provided in the 
supplementary material section. 
 
Serology 
Serological testing for transglutaminase 2-specific IgA, antigliadin IgG and IgA 
(Aesku) and endomysium antibodies as well as HLA typing was undertaken in 
all patients prior to the biopsy at the regional immunology laboratory. None of 
the CD patients had IgA deficiency. All sera collected at baseline were tested 
for circulating anti-TG6 antibodies as part of the study using previously 
described methodology.8,9 
 
Gluten-free diet follow-up  
The first 52 patients were re-assessed after 1 year on GFD, including repeat 
brain imaging, clinical assessment via a telephone interview and serological 
status (to confirm adherence to diet). Due to limited funding it was not 
possible to re-assess the entire cohort at 1 year. 
 
Statistical analysis 
A database was developed using the Statistical Package for Social Science 
(version 23.0 for Mac; SPSS). Analyses sought to firstly characterize the 
significance of different measures at the point of presentation of these newly-
diagnosed CD patients, to secondly investigate differences in key MR 
variables relative to TG6 status, and to finally examine the progression in 
relation to MR variables in the 1 year follow-up group. Frequencies and 
descriptive statistics were examined for each variable. Comparisons between 
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groups were made by using the Student’s t-test for the normally distributed 
continuous variables and by using the Mann-Whitney’s U test for the non-
normally distributed continuous variables. Categorical variables were 
compared using the chi square test. Level of significance was set at the 95% 
confidence level. Statistical models employed to test significance of observed 
changes on imaging data are given in the Supplemental Materials section. 
 
Results  
A total of 100 consecutive newly diagnosed CD patients (60F and 40M) were 
recruited over an 18 months period. Reasons for referral included: one or 
more CD related gastrointestinal symptoms (abdominal bloating, abdominal 
pain, weight loss, diarrhea, pale stools) in 54% of patients, anaemia in 16%, 
family screening in 14%, persistent fatigue in 6%, irritable bowel syndrome 
diagnosed in primary care in 5%, osteoporosis in 4%, presence of other 
autoimmune diseases in 4% and abnormal liver function tests in 3%. The 
mean age at the time of diagnosis of CD was 43±15 years (range 19 to 77). In 
line with a CD diagnosis, 97% of patients had circulating IgA TG2 
autoantibodies, 90% had endomysium antibodies and 82% had circulating 
antibodies to gliadins (88% IgG, 75% IgA and 63% both).  All patients carried 
a CD susceptibility class II MHC, either HLA DQ2 (96%) or HLA DQ8 (4%). 
 
Clinical evaluation 
Detailed neurological history revealed complaints of gait instability in 24% of 
patients, persisting sensory symptoms in 12%, and 42% with frequent 
(weekly) headaches, whereby 21% had more than one of these 3 neurological 
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symptoms. On clinical examination, gait instability was found in 29% of 
patients. Sustained gaze-evoked nystagmus on lateral gaze was observed in 
11% (all apart from 1 of these 11 patients also had gait instability), and distal 
sensory loss and/or areflexia suggestive of peripheral neuropathy in 10%. A 
neurophysiological assessment of all 10 patients with clinically suspected 
peripheral neuropathy indicated that one had evidence of large fiber 
neuropathy and another had a small fiber neuropathy. In total 67/100 (67%) 
patients had symptoms and/or signs of neurological dysfunction (Table 1). 
Excluding headache, which as a sole neurological symptom was present in 
17% of patients, 50% of patients had symptoms and/or signs (balance 
problems, gait instability, sensory symptoms and sensory loss) of neurological 
dysfunction. We did not identify any other contributory factors that could 
potentially explain the above findings other than the presence of CD. 
 
Brain imaging 
MRI and MR spectroscopy was performed in 96 patients. Four patients did not 
have imaging, 2 due to claustrophobia, 1 was pregnant and one had a recent 
coronary stent insertion. In one patient the spectroscopy was unsuccessful for 
technical reasons. MR spectroscopy of the cerebellum was abnormal in 45/95 
(47%) patients, in 36 the abnormality was in the vermis (NAA/Cr ratio ≤0.95), 
in 25 in the hemisphere (NAA/Cr ratio ≤0.99) and in 16 in both. The 
prevalence of abnormal MR spectroscopy was not significantly different in 
patients with clinically overt balance problems and those without (53.1% vs 
42.2%; p=0.311). The number of patients with white matter lesions over and 
above what is expected from age was 24/96 (25%). This compared to 18/525 
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(3%) in healthy volunteers (p<0.001). There was no difference in the vascular 
risk factors or age between the group of patients with white matter changes 
and those without.  
 
Stratification for TG6 autoantibodies 
Serological testing for circulating TG6 antibodies was done in 98 patients and 
antibodies were present in 39 (40%) patients (TG6 IgA : 28, TG6 IgG: 22, and 
both:11), which is in line with previous cross-sectional cohort data from the 
UK.9 This compares to 4% in the healthy population.9  
Combined MR imaging and TG6 serology was available in 95 participants of 
which 37 (40%) had circulating autoantibodies to TG6. Patients with TG6 
antibodies (TG6+) were significantly older than those without (TG6-): 
46.7±14.8 vs 40.3±14.8 (t-test, p=0.043). Abnormal imaging alone was not 
significantly linked to the presence of TG6 antibodies (26/38 [68.4%] in TG6+ 
vs 29/57 [50.9%] in TG6-, p=0.09).  However, 28/38 (73.7%) of TG6+ patients 
had abnormal MRS of the cerebellum and/or balance problems compared to 
26/57 (45.6%) of TG6- patients (chi square, p=0.007). Table 2 summarizes 
these findings. 
To investigate in detail more specific imaging changes between the 2 groups 
we carried out a normalized brain volume (NBV) analysis for key regions. This 
revealed TG6+ patients to have significantly reduced cerebellar gray matter 
(GM) (NBVTG6+ / NBVTG6- = 7.554±0.808 / 7.869±0.718; independent t-test 
p=0.050), and subcortical GM (NBVTG6+ / NBVTG6- = 3.403±0.193 / 
3.503±0.192; p=0.016), but not cortical GM (NBVTG6+ / NBVTG6- = 
27.286±1.823 / 27.793±1.632; p=0.168) (Fig. 1). Given these findings, further 
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analysis that controlled for age and included sub-regions was undertaken. 
This revealed that, for the TG6+ group, NBV remained significantly reduced in 
the primary subcortical GM region, and was also significantly reduced in the 
thalamus, but not in any other comparison (Table 3). However, there was also 
a trend for abnormal atrophy in the TG6+ group in three further cerebellar 
regions of interest (VIIb, VIIIa and Crus II, p<0.07).  
FIRST “vertex” analysis was used to further investigate the significant finding 
in the thalamus. Models that did not control for age were first used to visualise 
the overall spatial pattern of atrophy between the two groups (Fig. 2a), 
showing a broad pattern of GM loss, with relative sparing of the anterior and 
pulvinar nuclei. With age correction applied (Fig. 2b), a significant locus of 
atrophy around the lateral / ventral posterior nuclei became evident. 
 
Follow-up after 1 year of GFD 
At one year, during telephone consultation with the first 52 patients recruited 
20/24 (83.3%) indicated that their headaches had significantly improved (in 
15) or completely resolved (in 5) following the introduction of GFD. 
All 52 patients underwent repeat brain imaging at one year (11.6 ± 1 month 
following baseline scan). Of the 23/52 patients who had abnormal NAA/Cr 
baseline vermian spectroscopy values, 12 (52.2%) improved to within the 
normal range after adoption of GFD. In 15 patients (29%) there was an 
increase in the number of white matter lesions on the second scan. All apart 
from one of these patients already had white matter abnormalities at baseline.  
It should be noted that at the time of their second scan, 20 (47%) out of 43 
patients that had repeat serological testing still had positive serology (all had 
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reduced levels compared to baseline but still positive for one or more of 
antigliadin, endomysium and TG2 antibodies; anti-TG6 antibody analysis was 
not performed at one year), suggesting inadequate compliance with GFD. We 
found no correlation between increased white matter lesions or change in MR 
spectroscopy and serological status at one year. The numbers however were 
very small.  
 
 
Discussion  
To our knowledge this is the largest prospective study to perform detailed 
neurological evaluation in patients with newly diagnosed CD presenting to 
gastroenterologists, using both clinical assessments and brain imaging 
including MR spectroscopy. The study suggests that a large proportion of 
patients with CD already have neurological symptoms and/or signs of 
neurological dysfunction at the time of diagnosis of CD: gait instability in 24% 
of patients, persisting sensory symptoms in 12%, and 42% with frequent 
headaches. Particularly notable was the presence of gait ataxia in 29% of CD 
patients on clinical examination.  
In addition 46% of patients had abnormal MR spectroscopy of the cerebellum 
and 25% had abnormal white matter lesions over and above what is expected 
from age (3% in healthy population). Such neurological involvement often fails 
to be identified as it is unreported by patients and not questioned by 
gastroenterologists. As all of these patients were from the local catchment 
area and referred by their local General Practitioners we believe that these 
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findings are representative for adult patients with CD presenting to 
gastroenterologists.  
TG6 autoantibodies have been proposed as an early marker for neurological 
involvement in gluten-related diseases, particularly ataxia.9 In addition to TG6 
autoimmunity, mutations of the TGM6 gene have also been linked to 
ataxia.14,15,16  Our data provide further support for the utility of this marker in 
newly-diagnosed CD patients as a surrogate for brain involvement, as TG6 
antibody positive patients displayed significant atrophy of subcortical brain 
regions, particularly the thalamus. TG6 is expressed in a subset of neurons in 
the cerebellar cortex (Purkinje cells) and cerebellar nuclei but also in the 
thalamus amongst other subcortical locations.16, 17 The thalamus is involved in 
motor control in terms of acting as a relay centre between the cerebellum and 
the motor cortex.18 The observed significant thalamic atrophy and tendency 
towards cerebellar atrophy are therefore in line with loss or impairment of 
TG6+ neurons, potentially affecting GABA-ergic inhibitory pathways. This is in 
keeping with recent publications demonstrating brain hyper-excitability in 
patients with CD.19, 20  
We have previously demonstrated that the prevalence of circulating TG6 
antibodies in CD patients presenting with ataxia is much higher than in those 
presenting to gastroenterologists (73% vs 40%), whereas the prevalence of 
TG6 antibodies in paediatric CD patients presenting to gastroenterologists 
was found to be 25%.21 The TG6 antibody prevalence in these 3 groups is 
analogous to what is observed in patients with DH where circulating TG3 
antibodies (antibodies against DH-specific epidermal autoantigen) are found 
in up to 71% of patients with DH but in only 50% and 11% of adult and 
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pediatric CD patients, respectively.22 It is noteworthy that in patients with DH, 
not all patients have circulating TG3 antibodies, yet 100% have IgA-TG3 
deposits in the papillary dermis, the site of the primary manifestation.23 
Therefore, while the presence of these antibodies (TG2, TG3 and TG6) in the 
serum is diagnostically helpful, their absence in the serum does not preclude 
a localized response at the level of the target tissue (gut, skin and brain). This 
observation may explain why some of the patients from this study who had 
neurological symptoms and signs and/or abnormal imaging were negative for 
TG6 antibodies as measured in the serum. Such patients may still be positive 
for TG6-specific plasma cells and have deposition of TG6 antibodies locally in 
the brain tissue which can only be assessed retrospectively, post-mortem. 
Indeed, the presence of such TG6 antibody deposits was demonstrated in the 
brain of gluten ataxia patients.24 Data on the serological prevalence of TG6 in 
different gluten sensitivity-related populations are sparse and have been 
collected by mainly using customized in-house TG6 antibody assays. One 
such study found the prevalence to be just 10% amongst a cohort of a mixture 
of neurology patients with CD or with just AGA positivity without 
enteropathy.25 Until such time as the widespread availability of a reliable and 
standardized commercial TG6 assay in everyday clinical practice becomes a 
reality, it is difficult to draw any major conclusions on the differences in 
prevalence between published studies.   
 
The prevalence of peripheral neuropathy in the current cohort was low at 2%. 
A Finnish study demonstrated evidence of peripheral neuropathy, using 
neurophysiology, in 23% of patients with established CD.26 A population 
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based epidemiological study from Sweden on 28,232 patients with CD 
showed a 2.5-fold increased risk for peripheral neuropathy.27  The low 
prevalence of peripheral neuropathy in our cohort suggests that gluten 
neuropathy may be a late manifestation of CD (the mean age at diagnosis of 
neuropathy in the Finish cohort was 51 compared to 43.8 in the cohort studied 
here). This is consistent with our observation that for patients with CD 
presenting with neuropathy the average age at diagnosis of CD was 67. 
 
Twenty five percent of patients had significantly increased number of white 
matter abnormalities on MR imaging corrected for age, when compared to 
healthy controls. Headaches, which subside with adherence to a GFD, and 
white matter abnormalities, which do not resolve, in CD have been previously 
reported and the term gluten encephalopathy has been used to describe such 
cases.28 The largest population study on CD and headache has shown a 
significantly increased risk of headache-related visits in patients with CD.29   
The majority of patients with CD and headache studied here indicated that 
their headache had improved or disappeared (80%) after a year on a strict 
gluten free diet. Similar percentage improvement (75%) has been reported in 
a recent systematic review of headache in the context of CD.30 This is 
consistent with an aetiological link between headache and CD. The 
observation of high prevalence of white matter abnormalities in patients with 
CD has also been reported in a smaller study of 17 patients who were on 
GFD.31 The concern over the white matter abnormalities on MR imaging is 
their potential contribution to cognitive decline. A large population study from 
Sweden has suggested that there is an increased risk of vascular dementia in 
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patients with CD.32 The aetiology of the headache in CD patients remains 
unclear but an interesting study demonstrated regional cerebral blood flow 
alteration (hypoperfusion) in patients with CD not on GFD when compared to 
healthy controls and patients with CD on GFD.33  
There are also some limitations as to what can be extrapolated from this 
study. We did not include a healthy control population to study alongside the 
CD group as the primary aim was to investigate differences between CD 
patients positive or negative for TG6 antibodies. It is therefore difficult to know 
how the prevalence of the clinical findings would compare to a healthy 
population examined in the same setting. However, the literature provides 
some guidance in this regard. A previous smaller cross-sectional study in 
patients with established CD (mean age 51 years), demonstrated clinical 
evidence of stance and gait instability in 33% of the patients, a figure similar 
to what we found.34 A study assessing the prevalence of gait instability in 115 
healthy volunteers with the same mean age as our group found that none of 
them had any evidence of gait instability.35 Another study in untreated patients 
with CD showed the presence of neurological symptoms to be 15% compared 
to 0% in the control group.36  
Only half of the cohort of patients neurologically assessed at baseline 
underwent repeat imaging at 1 year. This was due to limited funding. However 
the beneficial effect of GFD in patients with GA, using MR spectroscopy as 
the outcome measure has already been reported in a much larger cohort of 
117 patients.10 All aspects of the primary aim of this study encompassed 
relevant controls including TG6 serology and brain imaging, where data was 
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available from healthy controls both in terms of MR spectroscopy and white 
matter abnormalities and therefore no such limitations apply.  
In conclusion neurological dysfunction in patients with newly diagnosed CD 
presenting to the gastroenterologist is common but overlooked. TG6 
antibodies are prevalent amongst patients with newly diagnosed CD and are 
associated with regional brain atrophy. Given the early presence of 
neurological dysfunction including brain atrophy there is a need for increased 
awareness of the neurological manifestations amongst clinicians and 
reinforcement of adherence to a strict GFD by patients in order to avoid the 
potential of permanent neurological disability. 
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Figure legends 
 
Fig. 1     Brain atrophy in patients with TG6 autoantibodies.  
Box plots visualising normalized brain volumes (NBVs) for cerebral cortical 
(top left), subcortical (top right), and cerebellar cortical (bottom) GM for TG6 
antibody positive or negative CD patients (asterisk: p<0.05, independent t-
test).  
 
Fig. 2     Visualisation of TG6 antibody-related atrophy in the thalamus. 
TFCE-corrected output from FIRST “vertex” analysis of the thalamus before 
(A) and after (B) correction for age-related changes. A. Red locations highlight 
areas which have significantly (p≤0.05) atrophied in the TG6+ group 
compared to the TG6- group. B. Red areas as above while blue areas identify 
locations where (p≤0.1) for reference (top & middle); differences only reached 
significance in the left thalamus (middle). However, when reducing the 
threshold for red areas to p≤0.06 in the right thalamus, a very similar pattern 
to the left is revealed (bottom).  
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Table 1: Neurological assessment of newly diagnosed CD patients 
Number of patients with CD 
presenting to gastroenterologists 
recruited 
100 
Mean age at diagnosis 43±15 years (range 19-77) 
Total number with symptoms and/or 
signs of neurological dysfunction 
67% 
Symptoms gait instability 
loss of balance 
24% 
persisting 
sensory 
disturbance 
12% 
frequent 
headaches 
42% 
Signs gait ataxia 29% 
nystagmus 11% 
sensory loss 
and/or areflexia 
10% 
Excluding headache, total number 
with symptoms and signs of 
neurological dysfunction 
50% 
Abnormal MR spectroscopy of the 
cerebellum 
45/95 (47%) 
White matter abnormalities on MR 
brain imaging (excessive for age) 
25% (3% in healthy controls) 
Number of patients undergoing MR 
imaging at one year 
52/100  
Abnormal cerebellar spectroscopy 
at baseline 
23/52 (44.2%) 
Normalization of MR spectroscopy 
at one year 
12/23 (52.2%) 
Number TG6 positive CD patients 40% 
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Table 2: Differences between patients with CD positive for TG6 antibodies 
when compared to those who were negative for TG6 antibodies. 
 
 TG6 +ve TG6-ve p value 
age 46.7 40.3 0.043* 
abnormal 
imaging 
68.4% 50.9% 0.09 
abnormal 
spectroscopy of 
the cerebellum 
and gait ataxia 
73.7% 45.6% 0.007* 
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Table 3: Volumetric (NBV) analysis of individual brain regions following 
stratification of CD patients for TG6 autoantibody positivity revealed significant 
differences in age-controlled ANOVAs. 
 
         37 patients     58 patients 
	 ROI	 TG6+		Mean(SD)	NBV	 TG6-	Mean(SD)	NBV	 TG6				positivity	p	value	
Age	correct.		p	value	
Freesurfe
r Volumes 
Subcortical 
GM 
3.403(0.193
) 
3.503(0.192
) .045 .050 
Thalamus 0.928(0.066) 
0.973(0.085
) .035 .002 
Caudate 0.397(0.041) 
0.400(0.048
) .406 .015 
Putamen 0.581(0.072) 
0.604(0.054
) .221 .005 
Globus 
Pallidus 
0.177(0.022
) 
0.179(0.016
) .823 .025 
Hippocampu
s 
0.519(0.051
) 
0.523(0.040
) .750 .697 
Amygdala 0.175(0.022) 
0.182(0.017
) .096 .752 
SUIT 
Volumes 
Cerebellum 
GM 
7.554(0.808
) 
7.869(0.718
) .110 .097 
I-IV 0.449(0.053) 
0.470(0.048
) .121 .027 
V 0.588(0.061) 
0.608(0.054
) .154 .266 
VI 1.224(0.126) 
1.266(0.114
) .163 .218 
VIIb 0.619(0.063) 
0.645(0.057
) .065 .385 
VIIIa 0.589(0.061) 
0.615(0.055
) .055 .407 
VIIIb 0.478(0.052) 
0.497(0.045
) .118 .161 
IX 0.417(0.051) 
0.432(0.043
) .327 .004 
X 0.060(0.011) 
0.064(0.010
) .209 <.001 
Vermis 0.351(0.041) 
0.364(0.037
) .259 .024 
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Crus I 1.625(0.180) 
1.700(0.163
) .103 .027 
Crus II 1.155(0.120) 
1.207(0.110
) .064 .222 
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